47 related articles for article (PubMed ID: 20016227)
21. Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy.
Park SB; Lin CS; Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC
Brain; 2009 Oct; 132(Pt 10):2712-23. PubMed ID: 19745023
[TBL] [Abstract][Full Text] [Related]
22. Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity.
Park SB; Goldstein D; Lin CS; Krishnan AV; Friedlander ML; Kiernan MC
J Clin Oncol; 2009 Mar; 27(8):1243-9. PubMed ID: 19164207
[TBL] [Abstract][Full Text] [Related]
23. Oxaliplatin-induced neurotoxicity and the development of neuropathy.
Krishnan AV; Goldstein D; Friedlander M; Kiernan MC
Muscle Nerve; 2005 Jul; 32(1):51-60. PubMed ID: 15880395
[TBL] [Abstract][Full Text] [Related]
24. Lhermitte sign and urinary retention: atypical presentation of oxaliplatin neurotoxicity in four patients.
Taieb S; Trillet-Lenoir V; Rambaud L; Descos L; Freyer G
Cancer; 2002 May; 94(9):2434-40. PubMed ID: 12015768
[TBL] [Abstract][Full Text] [Related]
25. Utilizing natural activity to dissect the pathophysiology of acute oxaliplatin-induced neuropathy.
Park SB; Lin CS; Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC
Exp Neurol; 2011 Jan; 227(1):120-7. PubMed ID: 20965170
[TBL] [Abstract][Full Text] [Related]
26. Oxaliplatin-induced lhermitte's phenomenon as a manifestation of severe generalized neurotoxicity.
Park SB; Lin CS; Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC
Oncology; 2009; 77(6):342-8. PubMed ID: 20016227
[TBL] [Abstract][Full Text] [Related]
27. Oxaliplatin-related neurotoxicity: how and why?
Pasetto LM; D'Andrea MR; Rossi E; Monfardini S
Crit Rev Oncol Hematol; 2006 Aug; 59(2):159-68. PubMed ID: 16806962
[TBL] [Abstract][Full Text] [Related]
28. Oxaliplatin-associated neuropathy: a review.
Cersosimo RJ
Ann Pharmacother; 2005 Jan; 39(1):128-35. PubMed ID: 15590869
[TBL] [Abstract][Full Text] [Related]
29. Lhermitte's sign: Review with special emphasis in oncology practice.
Gemici C
Crit Rev Oncol Hematol; 2010 May; 74(2):79-86. PubMed ID: 19493683
[TBL] [Abstract][Full Text] [Related]
30. Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures.
Gamelin E; Gamelin L; Bossi L; Quasthoff S
Semin Oncol; 2002 Oct; 29(5 Suppl 15):21-33. PubMed ID: 12422305
[TBL] [Abstract][Full Text] [Related]
31. Lhermitte's sign and vitamin B12 deficiency: case report.
Teive HA; Haratz S; Zavala J; Munhoz RP; Scola RH; Werneck LC
Sao Paulo Med J; 2009; 127(3):171-3. PubMed ID: 19820879
[TBL] [Abstract][Full Text] [Related]
32. Resolution of Lhermitte's sign in multiple sclerosis by treatment with weak electromagnetic fields.
Sandyk R; Dann LC
Int J Neurosci; 1995 Apr; 81(3-4):215-24. PubMed ID: 7628912
[TBL] [Abstract][Full Text] [Related]
33. [Oxaliplatin neurotoxicity].
Gamelin L; Boisdron-Celle M; Morel A; Gamelin E
Bull Cancer; 2006 Feb; 93 Suppl 1():S17-22. PubMed ID: 16491518
[TBL] [Abstract][Full Text] [Related]
34. A systematic review of the symptomatic management of Lhermitte's phenomenon.
Lam L; Koopowitz S; Thompson A; Smith G; Tan S; Gupta A; Kovoor J; Harroud A; Bacchi S; Slee M
J Clin Neurosci; 2023 Oct; 116():32-36. PubMed ID: 37603922
[TBL] [Abstract][Full Text] [Related]
35. Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies.
Park SB; Krishnan AV; Lin CS; Goldstein D; Friedlander M; Kiernan MC
Curr Med Chem; 2008; 15(29):3081-94. PubMed ID: 19075655
[TBL] [Abstract][Full Text] [Related]
36. On the significance of Lhermitte's sign in oncology.
Ventafridda V; Caraceni A; Martini C; Sbanotto A; De Conno F
J Neurooncol; 1991 Apr; 10(2):133-7. PubMed ID: 1895161
[TBL] [Abstract][Full Text] [Related]
37. Preventing oxaliplatin-induced neurotoxicity: rationale and design of phase Ib randomized, double-blind, placebo-controlled, cross-over trials for early clinical evaluation of investigational therapeutics.
Han CH; Kilfoyle DH; Hill AG; Jameson MB; McKeage MJ
Expert Opin Drug Metab Toxicol; 2016 Dec; 12(12):1479-1490. PubMed ID: 27539508
[TBL] [Abstract][Full Text] [Related]
38. [Lhermitte's sign during lateral cervical puncture: survey of possible accidents in the lateral C1-C2 puncture and report of 2 cases of spinal cord penetration].
Rossitti SL; Balbo RJ
Arq Neuropsiquiatr; 1990 Sep; 48(3):341-7. PubMed ID: 2264789
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
